These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36279599)

  • 1. The symbol digit modalities test and the paced auditory serial addition test involve more than processing speed.
    Berrigan LI; LeFevre JA; Rees LM; Berard JA; Francis A; Freedman MS; Walker LAS
    Mult Scler Relat Disord; 2022 Dec; 68():104229. PubMed ID: 36279599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
    López-Góngora M; Querol L; Escartín A
    BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Information-processing speed is the primary deficit underlying the poor performance of multiple sclerosis patients in the Paced Auditory Serial Addition Test (PASAT).
    Forn C; Belenguer A; Parcet-Ibars MA; Avila C
    J Clin Exp Neuropsychol; 2008 Oct; 30(7):789-96. PubMed ID: 18608672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
    Castrogiovanni N; Mostert J; Repovic P; Bowen JD; Uitdehaag BMJ; Strijbis EMM; Cutter GR; Koch MW
    Neurology; 2023 Jul; 101(1):e1-e11. PubMed ID: 37072219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Neuropsychological Impairment in Relapsing Remitting Multiple Sclerosis: The Role of Clinical Measures, Treatment, and Neuropsychiatry Symptoms.
    Lozano-Soto E; Cruz-López ÁJ; Gutiérrez R; González M; Sanmartino F; Rashid-Lopez R; Espinosa-Rosso R; Forero L; González-Rosa JJ
    Arch Clin Neuropsychol; 2021 May; 36(4):475-484. PubMed ID: 33067616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
    Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
    Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Information processing speed and influential factors in multiple sclerosis].
    Zhang ML; Xu EH; Dong HQ; Zhang JW
    Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(15):1173-7. PubMed ID: 27117362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
    Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
    Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
    Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
    Stavrogianni K; Kitsos DK; Giannopapas V; Chasiotis AK; Christouli N; Paraskevas PG; Zompola C; Tsivgoulis G; Paraskevas GP; Giannopoulos S
    J Neuroimmunol; 2024 Feb; 387():578270. PubMed ID: 38176314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
    Strober L; DeLuca J; Benedict RH; Jacobs A; Cohen JA; Chiaravalloti N; Hudson LD; Rudick RA; LaRocca NG;
    Mult Scler; 2019 Nov; 25(13):1781-1790. PubMed ID: 30334474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Riccitelli GC; Pagani E; Rodegher M; Colombo B; Preziosa P; Falini A; Comi G; Filippi M; Rocca MA
    Mult Scler; 2019 Feb; 25(2):204-216. PubMed ID: 29173009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.
    Edgar C; Jongen PJ; Sanders E; Sindic C; Goffette S; Dupuis M; Jacquerye P; Guillaume D; Reznik R; Wesnes K
    BMC Neurol; 2011 Jun; 11():68. PubMed ID: 21649910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance.
    Sandry J; Simonet DV; Brandstadter R; Krieger S; Katz Sand I; Graney RA; Buchanan AV; Lall S; Sumowski JF
    Mult Scler Relat Disord; 2021 Jun; 51():102950. PubMed ID: 33887609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
    Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
    Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study.
    Friedova L; Rusz J; Motyl J; Srpova B; Vodehnalova K; Andelova M; Novotna K; Novotny M; Ruzickova H; Tykalova T; Kubala Havrdova E; Horakova D; Uher T
    J Clin Neurosci; 2019 Jul; 65():28-33. PubMed ID: 31072740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
    Wilken J; Traboulsee A; Nelson F; Ionete C; Kolind S; Fratto T; Kane R; Gandhi R; Rawlings AM; Roesch N; Ozog MA; DeLuca J;
    Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis.
    Sonder JM; Burggraaff J; Knol DL; Polman CH; Uitdehaag BM
    Mult Scler; 2014 Apr; 20(4):481-8. PubMed ID: 24019305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tests of information processing speed: what do people with multiple sclerosis think about them?
    Walker LA; Cheng A; Berard J; Berrigan LI; Rees LM; Freedman MS
    Int J MS Care; 2012; 14(2):92-9. PubMed ID: 24453739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive impairment and decline in different MS subtypes.
    Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Polman CH
    J Neurol Sci; 2006 Jun; 245(1-2):187-94. PubMed ID: 16643951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.